Literature DB >> 23700088

A novel OPA3 mutation revealed by exome sequencing: an example of reverse phenotyping.

Beenish Arif1, Kishore R Kumar, Philip Seibler, Franca Vulinovic, Amara Fatima, Susen Winkler, Gudrun Nürnberg, Holger Thiele, Peter Nürnberg, Ahmad Zeeshan Jamil, Anne Brüggemann, Ghazanfar Abbas, Christine Klein, Sadaf Naz, Katja Lohmann.   

Abstract

IMPORTANCE: We sought to unravel the genetic cause in a consanguineous Pakistani family with a complex neurological phenotype. OBSERVATIONS: Neurological and ophthalmological examination, including videotaping and fundoscopy, and genetic investigations, including homozygosity mapping and exome sequencing, were performed at the University of the Punjab and the University of Lübeck. Participants included 2 severely affected cousins from consanguineous parents, 10 of their reportedly unaffected relatives, and 342 Pakistani controls. Motor symptoms in the 2 patients started at the age of 3 to 4 years and included chorea, cerebellar ataxia, dystonia, and pyramidal tract signs. Genome-wide genotyping delineated 2 regions of homozygosity on chromosomes 13q12.11 to 13q12.13 and 19q12 to 19q13.41. Exome sequencing revealed 2 rare, homozygous variants (c.32 T>A [p.L11Q] in OPA3 and c.941 C>G [p.A314G] in TSHZ3) that segregated with the disease. Only the OPA3 variant was absent in the control subjects and predicted to be damaging. Subsequent ophthalmological assessment revealed bilateral optic atrophy in both patients. CONCLUSIONS AND RELEVANCE: Mutations in OPA3 have been reported in Costeff optic atrophy syndrome. We identify a novel missense mutation in OPA3 as the cause of a complex neurological disorder, expanding the OPA3 -linked phenotype by early-onset pyramidal tract signs and marked lower limb dystonia. Investigation of optic atrophy was initiated only after genetic analysis, a phenomenon referred to as reverse phenotyping.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23700088     DOI: 10.1001/jamaneurol.2013.1174

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  16 in total

1.  Recessive dystonia-ataxia syndrome in a Turkish family caused by a COX20 (FAM36A) mutation.

Authors:  Sarah Doss; Katja Lohmann; Philip Seibler; Björn Arns; Thomas Klopstock; Christine Zühlke; Karen Freimann; Susen Winkler; Thora Lohnau; Mario Drungowski; Peter Nürnberg; Karin Wiegers; Ebba Lohmann; Sadaf Naz; Meike Kasten; Georg Bohner; Alfredo Ramirez; Matthias Endres; Christine Klein
Journal:  J Neurol       Date:  2013-11-08       Impact factor: 4.849

Review 2.  Next generation sequencing and the future of genetic diagnosis.

Authors:  Katja Lohmann; Christine Klein
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

3.  Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78).

Authors:  Alejandro Estrada-Cuzcano; Shaun Martin; Teodora Chamova; Matthis Synofzik; Dagmar Timmann; Tine Holemans; Albena Andreeva; Jennifer Reichbauer; Riet De Rycke; Dae-In Chang; Sarah van Veen; Jean Samuel; Ludger Schöls; Thorsten Pöppel; Danny Mollerup Sørensen; Bob Asselbergh; Christine Klein; Stephan Zuchner; Albena Jordanova; Peter Vangheluwe; Ivailo Tournev; Rebecca Schüle
Journal:  Brain       Date:  2017-02       Impact factor: 13.501

4.  TFG associated hereditary spastic paraplegia: an addition to the phenotypic spectrum.

Authors:  Huma Tariq; Sadaf Naz
Journal:  Neurogenetics       Date:  2017-01-25       Impact factor: 2.660

5.  Autosomal-recessive SASH1 variants associated with a new genodermatosis with pigmentation defects, palmoplantar keratoderma and skin carcinoma.

Authors:  Jean-Benoît Courcet; Siham Chafai Elalaoui; Laurence Duplomb; Mariam Tajir; Jean-Baptiste Rivière; Julien Thevenon; Nadège Gigot; Nathalie Marle; Bernard Aral; Yannis Duffourd; Alain Sarasin; Valeria Naim; Emilie Courcet-Degrolard; Marie-Hélène Aubriot-Lorton; Laurent Martin; Jamal Eddin Abrid; Christel Thauvin; Abdelaziz Sefiani; Pierre Vabres; Laurence Faivre
Journal:  Eur J Hum Genet       Date:  2014-10-15       Impact factor: 4.246

6.  From the genetic code to neuromics.

Authors:  Roger N Rosenberg
Journal:  JAMA Neurol       Date:  2013-06       Impact factor: 18.302

7.  Clinical and molecular genetic findings in autosomal dominant OPA3-related optic neuropathy.

Authors:  Panagiotis I Sergouniotis; Rahat Perveen; Dawn L Thiselton; Konstantinos Giannopoulos; Marios Sarros; Jennifer R Davies; Susmito Biswas; Alec M Ansons; Jane L Ashworth; I Christopher Lloyd; Graeme C Black; Marcela Votruba
Journal:  Neurogenetics       Date:  2014-08-27       Impact factor: 2.660

8.  Two novel compound heterozygous mutations in OPA3 in two siblings with OPA3-related 3-methylglutaconic aciduria.

Authors:  Christina Lam; Linda K Gallo; Richard Dineen; Carla Ciccone; Heidi Dorward; George E Hoganson; Lynne Wolfe; William A Gahl; Marjan Huizing
Journal:  Mol Genet Metab Rep       Date:  2014-01-01

9.  Disrupted mitochondrial function in the Opa3L122P mouse model for Costeff Syndrome impairs skeletal integrity.

Authors:  Alice E Navein; Esther J Cooke; Jennifer R Davies; Terence G Smith; Lois H M Wells; Atsushi Ohazama; Christopher Healy; Paul T Sharpe; Sam L Evans; Bronwen A J Evans; Marcela Votruba; Timothy Wells
Journal:  Hum Mol Genet       Date:  2016-04-22       Impact factor: 6.150

10.  Defining the genetic basis of early onset hereditary spastic paraplegia using whole genome sequencing.

Authors:  Kishore R Kumar; G M Wali; Mahesh Kamate; Gautam Wali; André E Minoche; Clare Puttick; Mark Pinese; Velimir Gayevskiy; Marcel E Dinger; Tony Roscioli; Carolyn M Sue; Mark J Cowley
Journal:  Neurogenetics       Date:  2016-09-28       Impact factor: 2.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.